A Blood Test for Chronic Fatigue Syndrome

[Guest guest]

Chronix Biomedical and Hemispherx Biopharma Jointly File Patent Application for

a Blood Test for Chronic Fatigue Syndrome (CFS)

Chronix Technology Focuses on Changes to CFS Patients' DNA

Hemispherx and Chronix Plan Studies to Validate Technology as a Potential

Diagnostic Test for CFS

SAN JOSE, Calif., March 3, 2011 (GLOBE NEWSWIRE) -- Chronix Biomedical

( " Chronix " ) announced today that it filed a provisional United States patent

application jointly with Hemispherx Biopharma, Inc. (NYSE Amex:HEB)

( " Hemispherx " ) on a blood test for Chronic Fatigue Syndrome ( " CFS " ). Patients

with CFS exhibit a wide range of disabling symptoms including the inability to

overcome fatigue by rest, swollen lymph nodes and cognitive deficiencies. CFS is

estimated to affect approximately 4 million Americans, according to the Centers

for Disease Control and Prevention (CDC). The disorder has a negative economic

impact in the United States estimated at more than $9 billion annually.

The Chronix experimental approach analyzes fragments of DNA often released into

the bloodstream during the process of apoptosis or programmed cell death.

Chronix is using its proprietary technology and advanced DNA sequencing

platforms to measure alterations in specific regions of the chromosome, which

can be detected as distinctive " signatures " in cell-free blood-borne DNA. By

focusing on these signatures, Chronix's technology can detect the presence of

disease-damaged cells in simple blood samples without needing to biopsy diseased

cells or tissues.

" Our technology -- based on DNA released into the bloodstream by dying and

damaged cells -- taps into the dynamic information provided by the genomic

alterations unique to each diseased cell. We capture what is happening to the

DNA very early in and throughout the disease process, in real time, and patient

by patient. That's how our approach differs from other tests that focus on

static genomic data or protein biomarkers, " said Dr. Urnovitz. The

patient-unique signatures captured by the Chronix technology may prove useful as

a companion diagnostic -- a test that is used to help guide treatment decisions

-- and to provide information about the disease process to help pharmaceutical

companies select the most efficacious drug candidates.

Use of the Chronix diagnostic technology in CFS will be evaluated in a study

being planned by Chronix and Hemispherx, a leader in CFS pharmaceutical

research. Dr. , Hemispherx CEO, commented, " It is with great

enthusiasm that we will be conducting studies aimed at validating the utility of

the Chronix technology to identify how different individuals can respond to

Hemispherx's experimental drug Ampligen®. "

The Chronix Biomedical blood test for Chronic Fatigue Syndrome is experimental

in nature and has not been evaluated by any regulatory agency. It is currently

limited to investigational use.

http://finance./news/Chronix-Biomedical-and-pz-1579465909.html?x=0 & .v=1

(If I remember right ampligen did work on 75% of the people in the test they did

last year. But since they could not prove that it worked the FDA did not approve

ampligen. The second test should be over any day now, and as best I can tell

resubmited it for approval.)

And maybe with this new blood test. It maybe more solid, and less chance for the

medical insurance companys not to pay for it.